Indications and uses
A moisture barrier that prevents and helps protect skin irritations from urine diarrhea perspiration fistula drainage feeding tube site leakage wound drainage minor burns cuts scrapes itching
A moisture barrier that prevents and helps protect skin irritations from urine diarrhea perspiration fistula drainage feeding tube site leakage wound drainage minor burns cuts scrapes itching
When practical, gently cleanse and dry area. Adults: Apply externally to affected area up to 6 times daily or after each incontinent episode or diaper change. Children under 12 years: Consult a doctor.
Store at 15-30°C (59-86°F)
Menthol 0.45%
Calamine 2%
Zinc Oxide 18%
External Analgesic, Skin Protectant
A moisture barrier that prevents and helps protect skin irritations from
Stop use and ask doctor if :
When practical, gently cleanse and dry area.
Store at 15-30°C (59-86°F)
Beeswax, Disodium EDTA, Glycerin, Lanolin, Methylparaben, Mineral Oil, Petrolatum, Propylparaben, Purified Water, Sodium Borate, Sorbitan Sesquioleate
First Choice Medical Supply
127 Interstate Dr.
Richland, MS 39218
800-809-4556 or visit
www.fcms.com
Item # 33433
CalmafxSachet.jpg calmafxtube.jpg
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1373249 | calamine 2 % / menthol 0.45 % / zinc oxide 18 % Topical Ointment | PSN | 4 |
| 1373254 | CalmaFX 2 % / 0.45 % / 18 % Topical Ointment | PSN | 4 |
| 1373254 | calamine 0.02 MG/MG / menthol 0.0045 MG/MG / zinc oxide 0.18 MG/MG Topical Ointment [Calmafx] | SBD | 4 |
| 1373249 | calamine 0.02 MG/MG / menthol 0.0045 MG/MG / zinc oxide 0.18 MG/MG Topical Ointment | SCD | 4 |
| 1373249 | Calamine 0.02 MG/MG / Menthol 0.0045 MG/MG / ZNO 0.18 MG/MG Topical Ointment | SY | 4 |
| 1373254 | Calamine 0.02 MG/MG / Menthol 0.0045 MG/MG / ZNO 0.18 MG/MG Topical Ointment [Calmafx] | SY | 4 |
| 1373249 | calamine 2 % / menthol 0.45 % / zinc oxide 18 % Topical Ointment | SY | 4 |
| 1373254 | CalmaFX (calamine 2 % / menthol 0.45 % / zinc oxide 18 % ) Topical Ointment | SY | 4 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 75904-3246-0 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d4a2-cd31-e053-dbdaa90ab51a | CalmaFX Moisture Barrier Ointment Drug Facts |
| 75904-3246-3 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d4a2-cd31-e053-dbdaa90ab51a | CalmaFX Moisture Barrier Ointment Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 75904-3246-0 | CalmaFXMoisture Barrier | 113 g in 1 TUBE | OINTMENT | 113 | 4 | |
| 75904-3246-3 | CalmaFXMoisture Barrier | 5 g in 1 POUCH | OINTMENT | 5 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 75904-3246 | CALMAFX MOISTURE BARRIER (MENTHOL, CALAMINE, ZINC OXIDE) OINTMENT [FIRST CHOICE MEDICAL SUPPLY] | 4 | Legacy NDC, 2 package rows | 20130325_7b52374e-1119-4145-b87b-96b7212fdc3e.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| FERRIC OXIDE RED | ACTIVE INGREDIENT | 1K09F3G675 | 4 | |
| MENTHOL | ACTIVE INGREDIENT | L7T10EIP3A | 4 | |
| ZINC OXIDE | ACTIVE INGREDIENT | SOI2LOH54Z | 4 | |
| FERRIC OXIDE RED | ACTIVE MOIETY | 1K09F3G675 | 4 | |
| MENTHOL | ACTIVE MOIETY | L7T10EIP3A | 4 | |
| ZINC OXIDE | ACTIVE MOIETY | SOI2LOH54Z | 4 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| LANOLIN | INACTIVE INGREDIENT | 7EV65EAW6H | 4 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 4 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 4 | |
| PETROLATUM | INACTIVE INGREDIENT | 4T6H12BN9U | 4 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 4 | |
| SODIUM BORATE | INACTIVE INGREDIENT | 91MBZ8H3QO | 4 | |
| SORBITAN SESQUIOLEATE | INACTIVE INGREDIENT | 0W8RRI5W5A | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 | |
| YELLOW WAX | INACTIVE INGREDIENT | 2ZA36H0S2V | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 75904-3246 | 75904-3246-3, 75904-3246-0 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MENTHOL | L7T10EIP3A | ACTIB |
| FERRIC OXIDE RED | 1K09F3G675 | ACTIB |
| ZINC OXIDE | SOI2LOH54Z | ACTIB |
| YELLOW WAX | 2ZA36H0S2V | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| LANOLIN | 7EV65EAW6H | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| MINERAL OIL | T5L8T28FGP | IACT |
| PETROLATUM | 4T6H12BN9U | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
| SORBITAN SESQUIOLEATE | 0W8RRI5W5A | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAMUSCULAR | 0.02 %w/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SYSTEM / TOPICAL | 42 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM / BUCCAL | 0.22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| LANOLIN | LANOLIN | 7EV65EAW6H | OINTMENT / RECTAL | 105 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRA-ARTICULAR | 0.03 %w/v | ||
| LANOLIN | LANOLIN | 7EV65EAW6H | OINTMENT / TOPICAL | 10 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.4 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / NASAL | 100 mg/100ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / RECTAL | 271 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRA-ARTICULAR | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / PARENTERAL | 30 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVENOUS | 10 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SOFT TISSUE | 0.02 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| LANOLIN | LANOLIN | 7EV65EAW6H | SPRAY / NASAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | CREAM / TOPICAL | NA | ||
| YELLOW WAX | YELLOW WAX | 2ZA36H0S2V | TABLET / ORAL | 3.22 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CAPSULE / VAGINAL | NA | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, EXTENDED RELEASE / ORAL | 10 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAVENOUS | 7 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CONCENTRATE / ORAL | 20 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / OPHTHALMIC | 396 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | ENEMA / RECTAL | 60 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INFILTRATION | 80 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| YELLOW WAX | YELLOW WAX | 2ZA36H0S2V | TABLET, COATED / ORAL | 213.7 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, ORALLY DISINTEGRATING / ORAL | 3 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION/ DROPS / OPHTHALMIC | 0.01 %w/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVASCULAR | 0.48 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 0.4 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM, SOLUBLE / BUCCAL | 1 mg | ||
| YELLOW WAX | YELLOW WAX | 2ZA36H0S2V | TABLET, EXTENDED RELEASE / ORAL | 0.01 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 15 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SUSPENSION / ORAL | 75 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5ba9ed70-fdbd-435c-ae6f-b6f14e573bca | 7b52374e-1119-4145-b87b-96b7212fdc3e | 2013-03-22 | Warnings | 5ba9ed70-fdbd-435c-ae6f-b6f14e573bca 7b52374e-1119-4145-b87b-96b7212fdc3e |
Adverse event summaries are temporarily unavailable. Other product information remains available.